Aviragen Therapeutics Inc Stock Nasdaq
Stocks
US0906941002
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 27/06 | Vaxart Publishes Presentation to Shareholders | CI |
| 26/06 | Vaxart Provides Update to Barda Funding Award for Covid-19 Oral Pill Vaccine Trial | CI |
| Market Cap | 130M 114M 105M 98.5M 185M 12.28B 189M 1.26B 489M 6.07B 489M 478M 21.04B | P/E 2026 * |
1.86x | P/E 2027 * | -0.56x |
|---|---|---|---|---|---|
| Enterprise Value | 130M 114M 105M 98.5M 185M 12.28B 189M 1.26B 489M 6.07B 489M 478M 21.04B | EV / Sales 2026 * |
0.37x | EV / Sales 2027 * | - |
| Free-Float |
98.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Aviragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Steven Lo
CEO | Chief Executive Officer | 60 | 18/03/2024 |
Sean Tucker
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/03/2024 |
Jeroen Grasman
DFI | Director of Finance/CFO | - | 19/05/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
David Wheadon
BRD | Director/Board Member | 68 | 21/04/2021 |
William Watson
BRD | Director/Board Member | 76 | 04/08/2022 |
Elaine Heron
BRD | Director/Board Member | 79 | 01/04/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.03% | -1.48% | +66.92% | +121.59% | 55.63B | |
| +0.82% | +15.05% | +79.52% | +88.67% | 52.25B | |
| +0.98% | +2.42% | -13.24% | -13.67% | 23.07B | |
| +1.45% | +7.67% | +5.49% | +422.47% | 22.41B | |
| +6.78% | +14.77% | +37.54% | -1.86% | 17.32B | |
| +1.10% | +4.05% | +30.99% | -32.05% | 15.94B | |
| +1.69% | +8.12% | +25.97% | +192.83% | 13.77B | |
| -3.35% | +8.96% | +134.32% | +282.61% | 13.47B | |
| +4.21% | +11.01% | +33.13% | - | 12.43B | |
| Average | +1.51% | +4.78% | +44.52% | +132.57% | 25.14B | |
| Weighted average by Cap. | +1.16% | +5.13% | +50.46% | +123.75% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 356M 312M 288M 269M 505M 33.57B 515M 3.46B 1.34B 16.59B 1.34B 1.31B 57.54B | - |
| Net income | 116M 102M 93.75M 87.77M 165M 10.94B 168M 1.13B 436M 5.41B 436M 426M 18.75B | -284M -249M -230M -215M -403M -26.79B -411M -2.76B -1.07B -13.24B -1.07B -1.04B -45.91B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
